Marcelo Cerullo1, Faiz Gani1, Sophia Y Chen1, Joseph K Canner1, Joseph M Herman2, Daniel Laheru3, Timothy M Pawlik4. 1. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. 2. Department of Radiation Oncology and Medical Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD. 3. Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD. 4. Department of Surgery, Wexner Medical Center at The Ohio State University, Columbus, OH.
Abstract
OBJECTIVE: The aim of this study is to assess the financial burden associated with treatment options for resectable pancreatic cancer. BACKGROUND: As the volume of cancer care increases in the United States, there is growing interest among both clinicians and policy-makers to reduce its financial impact on the healthcare system. However, costs relative to the survival benefit for differing treatment modalities used in practice have not been described. METHODS: Patients undergoing resection for pancreatic cancer were identified in the Truven Health MarketScan database. Associations between chemoradiation therapies and survival were performed using parameterized multivariable accelerated failure time models. Median payments over time were calculated for surgery, chemoradiation, and subsequent hospitalizations. RESULTS: A total of 2408 patients were included. Median survival among all patients was 21.1 months [95% confidence interval (CI): 19.8-22.5 months], whereas median follow-up time was 25.1 months (95% CI: 23.5-26.5 months). After controlling for comorbidity, receipt of neoadjuvant therapy, and nodal involvement, a longer survival was associated with undergoing combination gemcitabine and nab-paclitaxel [time ratio (TR) = 1.26, 95% CI: 1.02-1.57, P = 0.035) or capecitabine and radiation (TR = 1.25, 95% CI: 1.04-1.51, P = 0.018). However, median cumulative payments for gemcitabine with nab-paclitaxel were highest overall [median $74,051, interquartile range (IQR): $38,929-$133,603). CONCLUSIONS: Total payments for an episode of care relative to improvement in survival vary significantly by treatment modality. These data can be used to inform management decisions about pursuing further care for pancreatic cancer. Future investigations should seek to refine estimates of the cost-effectiveness of different treatments.
OBJECTIVE: The aim of this study is to assess the financial burden associated with treatment options for resectable pancreatic cancer. BACKGROUND: As the volume of cancer care increases in the United States, there is growing interest among both clinicians and policy-makers to reduce its financial impact on the healthcare system. However, costs relative to the survival benefit for differing treatment modalities used in practice have not been described. METHODS:Patients undergoing resection for pancreatic cancer were identified in the Truven Health MarketScan database. Associations between chemoradiation therapies and survival were performed using parameterized multivariable accelerated failure time models. Median payments over time were calculated for surgery, chemoradiation, and subsequent hospitalizations. RESULTS: A total of 2408 patients were included. Median survival among all patients was 21.1 months [95% confidence interval (CI): 19.8-22.5 months], whereas median follow-up time was 25.1 months (95% CI: 23.5-26.5 months). After controlling for comorbidity, receipt of neoadjuvant therapy, and nodal involvement, a longer survival was associated with undergoing combination gemcitabine and nab-paclitaxel [time ratio (TR) = 1.26, 95% CI: 1.02-1.57, P = 0.035) or capecitabine and radiation (TR = 1.25, 95% CI: 1.04-1.51, P = 0.018). However, median cumulative payments for gemcitabine with nab-paclitaxel were highest overall [median $74,051, interquartile range (IQR): $38,929-$133,603). CONCLUSIONS: Total payments for an episode of care relative to improvement in survival vary significantly by treatment modality. These data can be used to inform management decisions about pursuing further care for pancreatic cancer. Future investigations should seek to refine estimates of the cost-effectiveness of different treatments.
Authors: Skye C Mayo; Hari Nathan; John L Cameron; Kelly Olino; Barish H Edil; Joseph M Herman; Kenzo Hirose; Richard D Schulick; Michael A Choti; Christopher L Wolfgang; Timothy M Pawlik Journal: Cancer Date: 2011-09-20 Impact factor: 6.860
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy Journal: Oncologist Date: 2013-02-26
Authors: Stella Chang; Stacey R Long; Lucie Kutikova; Lee Bowman; William H Crown; Gary H Lyman Journal: Oncology Date: 2006-02-06 Impact factor: 2.935
Authors: Juan W Valle; Daniel Palmer; Richard Jackson; Trevor Cox; John P Neoptolemos; Paula Ghaneh; Charlotte L Rawcliffe; Claudio Bassi; Deborah D Stocken; David Cunningham; Derek O'Reilly; David Goldstein; Bridget A Robinson; Christos Karapetis; Andrew Scarfe; Francois Lacaine; Juhani Sand; Jakob R Izbicki; Julia Mayerle; Christos Dervenis; Attila Oláh; Giovanni Butturini; Pehr A Lind; Mark R Middleton; Alan Anthoney; Kate Sumpter; Ross Carter; Markus W Büchler Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: Cheryl K Zogg; Taylor D Ottesen; Kareem J Kebaish; Anoop Galivanche; Shilpa Murthy; Navin R Changoor; Donald L Zogg; Timothy M Pawlik; Adil H Haider Journal: J Gastrointest Surg Date: 2018-06-26 Impact factor: 3.452
Authors: Jin G Choi; Ryan D Nipp; Angela Tramontano; Ayman Ali; Tiannan Zhan; Pari Pandharipande; Emily C Dowling; Cristina R Ferrone; Theodore S Hong; Deborah Schrag; Carlos Fernandez-Del Castillo; David P Ryan; Chung Yin Kong; Chin Hur Journal: Oncologist Date: 2018-12-17
Authors: Myles A Ingram; Brianna N Lauren; Yoanna Pumpalova; Jiheum Park; Francesca Lim; Susan E Bates; Fay Kastrinos; Gulam A Manji; Chung Yin Kong; Chin Hur Journal: Cancer Rep (Hoboken) Date: 2022-02-05